McKesson (MCK) Q3 2026 Earnings
McKesson reported Q3 2026 revenue of $106.16B (+11.4% YoY), beat analyst consensus of $105.80B by $362.8M. Diluted EPS came in at $9.34 (+16.3% YoY), beat the $9.17 consensus by $0.17. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Financial Snapshot
Trailing eight quarters through Q3 2026
Q3 2026 Earnings FAQ
Common questions about McKesson's Q3 2026 earnings report.
McKesson (MCK) reported Q3 2026 earnings on February 4, 2026 after market close.
McKesson reported revenue of $106.16B and diluted EPS of $9.34 for Q3 2026.
Revenue beat the consensus estimate of $105.80B by $362.8M. EPS beat the consensus estimate of $9.17 by $0.17.
Compared to the same quarter a year prior, revenue grew 11.4% from $95.3B a year earlier and diluted EPS grew 16.3% from $8.03.
You can read the 8-K earnings release (0000927653-26-000015) and the 10-Q periodic report (0000927653-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.